Page last updated: 2024-12-08
prednisolone 21-3-sulfobenzoate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
prednisolone 21-3-sulfobenzoate: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 181625 |
CHEMBL ID | 2111103 |
CHEBI ID | 135823 |
MeSH ID | M0060819 |
Synonyms (18)
Synonym |
---|
prednisolone metasulfobenzoate |
CHEBI:135823 |
prednisolone sulfobenzoate |
3-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylbenzenesulfonic acid |
39175-74-1 |
pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, mono(3-sulfobenzoate), (11beta)- |
pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-((3-sulfobenzoyl)oxy)-, (11beta)- |
prednisolone 21-3-sulfobenzoate |
unii-sr3yx73fw2 |
solupred |
sr3yx73fw2 , |
3694-41-5 |
prednisolone 21-m-sulfobenzoate |
CHEMBL2111103 |
DTXSID20190432 |
pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-((3-sulfobenzoyl)oxy)-, (11.beta.)- |
atl 2502; cortico-sol; predenema; predfoam |
3-((2-((8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)carbonyl)benzenesulfonic acid |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" In view of the low plasma prednisolone concentrations obtained, there are theoretical advantages in using a poorly absorbed enema to avoid the possibility of systemic steroid effects in patients requiring long term steroid treatment." | ( Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Berghouse, L; English, J; Lennard-Jones, JE; Macrae, FA; McIntyre, PB, 1985) | 0.27 |
"Predocol is an oral preparation of a poorly absorbed salt of prednisolone that is effective in reducing inflammation over short treatment periods in patients with active ulcerative colitis." | ( Oral prednisolone metasulphobenzoate in the treatment of active ulcerative colitis. Balan, K; Binnie, JA; Cameron, EA; Middleton, SJ; Skerratt, SA; Solanki, C; Swift, A, 2003) | 0.32 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Treatment with steroid enemas resulted in symptomatic and sigmoidoscopic evidence of improvement more frequently than treatment with a dosage of oral steroid calculated to achieve similar plasma prednisolone levels." | ( A comparison of prednisolone enemas with low-dose oral prednisolone in the treatment of acute distal ulcerative colitis. Axon, AT; Dickinson, RJ; Dixon, MF; Hamilton, I; Pinder, IF; Ruddell, WS, 1984) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
corticosteroid hormone | Any of a class of steroid hormones that are produced in the adrenal cortex. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (25.00) | 18.7374 |
1990's | 4 (25.00) | 18.2507 |
2000's | 8 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.32
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.32) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 7 (41.18%) | 5.53% |
Reviews | 1 (5.88%) | 6.00% |
Case Studies | 3 (17.65%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (35.29%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |